Please assess the completion status of the following clinical trial:

Trial Title: Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - 80, male or non-pregnant female;~2. patients have unruptured aneurysm who plan to undergo intracranial stent placement;~3. patients with less than 2 of modified Rankin scale score at the day of enrollment;~4. patients who is able to understand the objective of the trial, agrees and signs the written informed consent form.~Exclusion Criteria:~1. The complications related to operation or material quality, such as guidewire pierces out blood vessel, coil herniation, incompletely opened stent, etc;~2. Simultaneous treatment of other cerebrovascular diseases, such as intracranial arteriovenous malformation, Intracranial arteriovenous fistula, etc;~3. Patient with history of hypersensitivity of aspirin, clopidogrel, or ticagrelor;~4. Patients with preoperative prophylactic use of tirofiban;~5. Patients with a high possibility of active bleeding, such as symptomatic intracranial hemorrhage or active gastric ulcer; or patients with coagulopathy;~6. Patients with thrombocytopenia (platelet count \<100,000/mm3 within three months before enrollment);~7. patient using anticoagulant;~8. Pregnant or lactating women;~9. Patients with malignant diseases, such as liver disease, kidney disease, congestive heart failure, malignant tumors, etc;~10. Poor compliance patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Monitoring Arm (Type: EXPERIMENTAL): Randomization: based on light transmittance aggregometry, modified dose of antiplatelet therapy(aspirin and ticagrelor) was used for high platelet reactivity(HPR) patients with intracranial stent placement, and standard antiplatelet regimen(aspirin and clopidogrel) was used in non-HPR patients.
- Conventional Arm (Type: EXPERIMENTAL): Randomization: without light transmittance aggregometry, standard antiplatelet regimen was used for unruptured aneurysm patients with intracranial stent.

Based on this trial design, predict the completion outcome and termination type (if applicable).